- Summits
- Sponsorship
- Get Tickets
- Retreats
- Media Opportunities
- News
- About
For MedTech startups, attracting investment involves more than presenting an innovative technology. Investors need to understand whether a solution addresses a meaningful healthcare need, has a viable route to market and can ultimately become a sustainable business.
As the MedTech investment landscape evolves, founders preparing for their next funding conversation will need to demonstrate more than a compelling idea.
Here are five areas investors are likely to examine when evaluating MedTech opportunities in 2027.
Innovation alone does not make a MedTech company investable.
Investors want to understand the problem being solved, who experiences it and how significant that problem is. A strong proposition connects the technology to a clearly defined unmet clinical need and demonstrates why the existing standard of care may not be sufficient.
The stronger the connection between the technology and the healthcare problem, the easier it becomes to communicate its potential value.
In MedTech, promising technology needs evidence behind it.
Depending on the company’s stage, investors may look at preclinical data, clinical evidence, real-world results, validation studies or other milestones that demonstrate the technology is moving beyond the concept stage.
Evidence can also help reduce some of the uncertainty associated with technical and clinical risk.
Regulatory approval is only part of the journey.
Investors also need to understand how a product will reach the market, what regulatory milestones remain and whether there is a credible route to reimbursement and adoption. These considerations can have a significant impact on timelines, costs and commercial potential.
For founders, being able to explain the regulatory and reimbursement pathway clearly can be just as important as explaining the technology itself.
A strong clinical solution still needs a viable market.
Investors may examine the size of the opportunity, the competitive landscape, potential customers and whether healthcare providers are likely to adopt the technology. Increasingly, commercialisation questions sit alongside technology and clinical considerations when assessing a MedTech company’s potential.
The question is not simply, “Is this a good product?”
It is also, “Who will use it, who will pay for it and how can the company scale?”
MedTech companies operate across clinical, regulatory, technical and commercial environments.
That makes the founding and leadership team an important part of the investment conversation. Investors need confidence that the people behind the technology understand the challenges ahead and have the expertise, partnerships and ability to execute their plans.
A compelling technology can open the door. Execution determines how far it can go.
Understanding what investors may be looking for is one thing. Getting your company in front of them is another.
At MedTech World Europe 2026, the Startup Pitch Competition will give 10 selected MedTech startups the opportunity to showcase their solutions to a jury of active investors and industry professionals.
Taking place from 11–13 November at the historic Mediterranean Conference Centre in Valletta, the event is the biggest MedTech World conference yet, bringing together more than 2,000 delegates across the global MedTech ecosystem.
The competition is supported by Ascend CRO, Blue Goat Cyber, Malta Enterprise and Prolucid Technologies.
The 2026 Malta pitch winner will receive:
Startup Pass holders are eligible to be considered for the final 10 and also receive a 1m x 1m branded Startup Kiosk, access to the Cultural Tour Experience, Awards Gala and Evening Reception, plus full access to the Conference & Exhibition.
Only 10 startups will be selected to pitch.
If your company is preparing for its next investment conversation, MedTech World Europe 2026 offers an opportunity to take that conversation from the pitch deck to the stage.
Secure your Startup Pass and put your startup forward for consideration.
